Encap Drug Delivery Receives Patent Approval for DuoCap Capsule System
|| Print ||
|Tuesday, 13 July 2010 09:30 (UTC + 2)|
Livingston, United Kingdom, July 13, 2010 / b3c newswire / - Encap Drug Delivery, a leading provider of development and manufacturing services to the pharmaceutical industry, has received confirmation that their DuoCap™, capsule delivery system has been granted patents for US and Europe.
DuoCap™, is a single oral dosage unit that comprises a capsule-in-a-capsule and offers broad therapeutic applications. The inner and outer capsules may contain the same active drug providing multiple release profiles from the dosage unit e.g. an immediate release formulation from the outer capsule and a controlled release formulation from the inner capsule. In addition to modifying the release profiles it is also possible to target the inner and outer capsule to different areas of the GI tract (small intestine or colon) using Encap’s coating expertise. Alternatively the compartments may contain different actives for use with combination therapies or actives that are incompatible in a single capsule. Combination therapies are of currently of significant interest, demonstrated by the recent launches of Combodart™ (GSK) and Vimovo™ (Pozen / AstraZeneca).
The patented Duocap™ technology can provide protection for clients interested in novel line-extension formulations for drugs coming to the end of their patent life. Encap’s business model is to provide clients with fee-for-service and license free formulation development and manufacturing service. DuoCap™ provides clients with the additional opportunity to license a patent protected technology on a product by product basis if required.
Encap Drug Delivery, Units 4, 5 & 6
Oakbank Park Way, Livingston
United Kingdom, EH53 0TH
Tel: +44 (0)1506 448080.